Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00329225 · ClinicalTrials.gov registry record · Phase 4

Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin

A Phase 4 study of Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 4
Development phase
630
Enrollment target
20
Study locations

NCT00329225 is a Phase 4 study of Diabetes Mellitus, Type 2 that has completed, run by GlaxoSmithKline. The registered enrollment target is 630 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00329225, a Phase 4 study of Diabetes Mellitus, Type 2, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 4
Development phase
630 participants
Enrollment target
20
Study locations

Study Summary

This 24-week study will compare the effects of adding the drug rosiglitazone (2mg and 4mg) or placebo to insulin in patients with Type 2 diabetes mellitus (non-insulin-dependent) who have not achieved their blood glucose goal using insulin alone. This study requires a total of seven visits during 28 weeks.

Conditions Studied

Diabetes Mellitus, Type 2

Interventions

  • DRUG rosiglitazone

Study Locations (20)

California

  • GSK Investigational Site - Concord
  • GSK Investigational Site - Fresno
  • GSK Investigational Site - Garden Grove
  • GSK Investigational Site - La Jolla
  • GSK Investigational Site - Long Beach
  • GSK Investigational Site - Los Angeles
  • GSK Investigational Site - Pasadena
  • GSK Investigational Site - Sacramento
  • GSK Investigational Site - Sacramento
  • GSK Investigational Site - Walnut Creek
  • GSK Investigational Site - West Hills

Alabama

  • GSK Investigational Site - Birmingham
  • GSK Investigational Site - Birmingham
  • GSK Investigational Site - Fairfield
  • GSK Investigational Site - Fultondale
  • GSK Investigational Site - Montgomery

Arizona

  • GSK Investigational Site - Phoenix
  • GSK Investigational Site - Phoenix

Arkansas

  • GSK Investigational Site - Jonesboro

Colorado

  • GSK Investigational Site - Centennial

Trial Details

FieldValue
Enrollment Target 630 participants
Start Date 2002-09
Est. Completion 2004-04
Phase Phase 4

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00329225

The ClinicalTrials.gov registry entry for NCT00329225 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 630 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (86% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which rosiglitazone is the first listed.

NCT00329225 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT00329225 about?

NCT00329225 is a clinical study titled "Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin". This 24-week study will compare the effects of adding the drug rosiglitazone (2mg and 4mg) or placebo to insulin in patients with Type 2 diabetes mellitus (non-insulin-dependent) who have not achieved their blood glucose goal using insulin alone. This study requires a total of seven visits during 28...

What is the current status of trial NCT00329225?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 630 participants. The study started on 2002-09. Estimated completion is 2004-04.

What conditions does trial NCT00329225 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT00329225?

The interventions under investigation include: rosiglitazone (DRUG).

Who is sponsoring clinical trial NCT00329225?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00329225 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Mellitus, Type 2

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.